Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 09:50 am Purchase | 2024-11-08 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | FMR LLC | 14,755,604 11.484% | 1,490,226 (+11.23%) | Filing History |
| 2024-11-08 10:34 am Sale | 2024-09-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | Wellington Management Group LLP | 5,018,779 3.910% | -2,234,128 (-30.80%) | Filing History |
| 2024-08-12 09:40 am Purchase | 2024-08-09 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | FMR LLC | 13,265,378 10.484% | 2,922,981 (+28.26%) | Filing History |
| 2024-07-05 10:24 am Sale | 2024-06-28 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BAILLIE GIFFORD & CO | 6,032,656 4.770% | -934,441 (-13.41%) | Filing History |
| 2024-02-13 4:59 pm Purchase | 2023-12-29 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | The Vanguard Group | 11,943,895 9.520% | 436,779 (+3.80%) | Filing History |
| 2024-02-09 6:14 pm Sale | 2024-02-07 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | Capital World Investors | 16,398,889 13.100% | -195,069 (-1.18%) | Filing History |
| 2024-02-09 08:40 am Purchase | 2023-12-29 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | Wellington Management Group LLP | 7,252,907 5.780% | 991,265 (+15.83%) | Filing History |
| 2024-02-09 08:35 am Sale | 2024-02-08 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | FMR LLC | 10,342,397 8.239% | -3,200,428 (-23.63%) | Filing History |
| 2024-01-29 12:18 pm Sale | 2023-12-29 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BAILLIE GIFFORD & CO | 6,967,097 5.550% | -2,440,774 (-25.94%) | Filing History |
| 2024-01-26 5:25 pm Sale | 2023-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BlackRock Inc. BLK | 8,546,557 6.800% | -119,145 (-1.37%) | Filing History |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | T. Rowe Price Associates, Inc. | 4,074,144 3.300% | -2,461,224 (-37.66%) | Filing History |
| 2023-02-13 2:49 pm Purchase | 2023-02-14 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | Capital World Investors | 16,593,958 13.500% | 3,777,181 (+29.47%) | Filing History |
| 2023-02-09 11:07 am Purchase | 2022-12-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | The Vanguard Group | 11,507,116 9.350% | 804,345 (+7.52%) | Filing History |
| 2023-02-09 08:23 am Sale | 2023-02-09 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | FMR LLC | 13,542,825 11.005% | -4,397,195 (-24.51%) | Filing History |
| 2023-02-06 2:43 pm Sale | 2022-12-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | Wellington Management Group LLP | 6,261,642 5.090% | -578,179 (-8.45%) | Filing History |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BlackRock Inc. BLK | 8,665,702 7.000% | 994,300 (+12.96%) | Filing History |
| 2023-01-19 12:08 pm Sale | 2022-12-30 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | BAILLIE GIFFORD & CO | 9,407,871 7.650% | -1,208,880 (-11.39%) | Filing History |
| 2022-09-09 12:30 pm Purchase | 2022-09-09 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | Capital World Investors | 12,816,777 10.700% | 12,816,777 (New Position) | Filing History |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | T. Rowe Price Associates, Inc. | 6,535,368 5.400% | 2,859,543 (+77.79%) | Filing History |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Alnylam Pharmaceuticals, Inc. ALNY | The Vanguard Group | 10,702,771 8.950% | 176,347 (+1.68%) | Filing History |